MarketCap
Facebook
X
TelegramAnnual report 2024
added 05-07-2025
Axon Enterprise Operating Cycle 2011-2026 | AXON
Annual Operating Cycle Axon Enterprise
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116 | 518 | 123 | 112 | 88.8 | 197 | 202 | 181 | 184 | 134 | 174 | 138 | 143 | 140 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 518 | 88.8 | 175 |
Quarterly Operating Cycle Axon Enterprise
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105 | - | - | 147 | 151 | 139 | - | 59.4 | 113 | 105 | - | 96.6 | 102 | 114 | - | 120 | 155 | 100 | - | 70 | 75.7 | 70.6 | - | 78.6 | 85.4 | 98.3 | - | 102 | 122 | 120 | - | 126 | 148 | 124 | - | 74.5 | 90 | 104 | - | 107 | 120 | 96.1 | - | 99.3 | 129 | 110 | - | 130 | 139 | 132 | - | 44.1 | 50.7 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 155 | 44.1 | 106 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
173 | $ 3.56 | 2.01 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.79 | -0.79 % | $ 4.31 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 6.63 | -0.75 % | $ 182 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | Canada |
 |
Anika Therapeutics
ANIK
|
325 | $ 14.36 | 1.13 % | $ 210 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
111 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
360 | $ 2.64 | 3.94 % | $ 16.6 M | USA |
 |
BioCardia
BCDA
|
101 | $ 1.27 | 0.79 % | $ 26.9 M | USA |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |